

Conference Feedback

Participant Information

Name: _____
 Title: _____
 Company: _____
 Telephone: _____

We have strived to ensure that every session at this conference was informative and compelling. We value your opinion and appreciate your cooperation.

Please return this survey to the conference registration desk or fax to: (617) 621-1620.

Please evaluate speakers' style and content on a scale from 1 (poor) - 5 (excellent)

Tuesday, April 28	Presentation		Additional Comments
	Style	Content	
Janet Woodcock, MD <i>Keynote Address: An Update on FDAAA One Year Later</i>	_____	_____	_____ _____ _____
Ellen Strahlman, MD, MHsc <i>Addressing the Need for More Real-World Data</i>	_____	_____	_____ _____ _____
Stella Blackburn, MA, MSc, FRCP(Ed), FFPM <i>Risk Management Initiatives in Europe</i>	_____	_____	_____ _____ _____
Robert Temple, MD <i>Risk Assessment in the 21st Century</i>	_____	_____	_____ _____ _____
Rekha Garg, MD, MS <i>Recent REMS Examples</i>	_____	_____	_____ _____ _____
Douglas Greene, MD <i>A Pharmaceutical Perspective: The Impact and Challenges of Meeting New Risk Management Requirements</i>	_____	_____	_____ _____ _____
Jan P. Vandembroucke, MD, PhD <i>Why Observational Evidence on Adverse Effects Can Be as Credible as Randomised Trials</i>	_____	_____	_____ _____ _____
Melissa A. Robb, RN <i>Safety Surveillance Initiatives Sentinel Initiative Case Example</i>	_____	_____	_____ _____ _____
Cynthia Sunstrum, MBA <i>Safety Surveillance Initiatives Canadian Drug Safety and Effectiveness Network (DSEN)</i>	_____	_____	_____ _____ _____
Kenneth J. Rothman, DrPH <i>Starting, Stopping, and Interpreting Safety Studies</i>	_____	_____	_____ _____ _____
Arthur Daemmerich, PhD <i>Drug Safety: A Historical and Business Perspective</i>	_____	_____	_____ _____ _____

Please evaluate speakers' style and content on a scale from 1 (poor) - 5 (excellent)

Wednesday, April 29

Style Content Additional Comments

Gail Wilensky, PhD
Political and Economic Forces Driving the Development of a Comparative Effectiveness Institute

Professor Peter Littlejohns, MBBS
Evidence-Based Data and Decision Making in the UK

Gilbert J. L'Italien, Sc.D
Case Presentation: Using a Registry for Reimbursement in Europe

Carolyn Clancy, MD
Implementing Evidence-Based Decision Making in the U.S.

Richard Toselli, MD, MBA
Industry Perspective: Challenges and Benefits of Conducting CE Research

Nancy Dreyer, PhD, MPH
Good Practice Principles for Observational Studies of Comparative Effectiveness: An Update on GRACE

Fadia T. Shaya, PhD, MPH
 Winston Wong, PharmD
Formulary Perspective: Evaluating Evidence for Reimbursement and Decision-Making

Sean Tunis, MD, MSc
Developing New Evidence for Reimbursement and What It Means for Health Plans

Nancy Dreyer, PhD, MPH
 Michael Peng, PhD, MPH
 Catherine M. Koeppe
Practical Issues With Real-World Studies

Conference Feedback
 Please return to the conference registration desk or fax to: (617) 621-1620.

Please Circle:	High		Low		
	5	4	3	2	1
Enough information prior to the conference?	5	4	3	2	1
Was the website informative?	5	4	3	2	1
Conference conducive to learning?	5	4	3	2	1
Was the registration process easy?	5	4	3	2	1
Was the staff knowledgeable and helpful?	5	4	3	2	1
Quality of the facilities:	5	4	3	2	1
Quality of the food:	5	4	3	2	1
Networking Reception:	5	4	3	2	1
Would you recommend the conference to a colleague?	5	4	3	2	1
Overall evaluation of the speakers and presentations:	5	4	3	2	1

What do you perceive to be the most pressing issues facing post-approval research in the next 6-12 months?

Who would you like to hear speak on these issues? (Please list their name, title and company)

Are there topics you felt should have been:

Added _____

Dropped _____

Additional Comments

Thank you for your time and consideration. We look forward to seeing you next year!